Drugs / Cenderitide
Cenderitide
Trials 7
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 14 trials | ||||||
| Phase 1 | NCT01316432 | May → Oct 2011 | congestive heart failure, symptomatic heart failure | Nile Therapeutics | Completed | No outcome recorded |
| Phase 1 | NCT00620308 | Jun 2008 → Feb 2012 | congestive heart failure | Mayo Clinic | Completed | No outcome recorded |
| Phase 1 | NCT00557661 | Nov 2007 → Dec 2008 | congestive heart failure | Nile Therapeutics | Completed | No outcome recorded |
| Phase 1 | NCT00482937 | Jan → May 2007 | congestive heart failure | Nile Therapeutics | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT02603614 | Dec 2015 → Mar 2016 | heart failure, impaired renal function disease | Capricor Inc. | Completed | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT02359227 | Jan → Apr 2015 | heart failure | Capricor Inc. | Completed | No outcome recorded |
| Phase 2 | NCT00839007 | Jun 2009 → Jun 2010 | heart failure | Nile Therapeutics | Completed | No outcome recorded |
| Comparator or background therapy4 trials | ||||||
| Phase 1 | NCT03091998 Comparator | Sep 2017 → May 2019 | heart failure | Mayo Clinic | Withdrawn | No outcome recorded Stop: Business |
| Phase 1 | NCT01407900 Comparator | Jan → Feb 2014 | impaired renal function disease, systolic heart failure | John A. Schirger | Withdrawn | No outcome recorded |
| Phase 1 | NCT02071602 Comparator | Oct 2013 → May 2018 | ST-elevation myocardial infarction | Mayo Clinic | Completed | No outcome recorded |
| Phase 1 | NCT01750905 Comparator | Apr 2013 → May 2016 | left ventricular failure | Mayo Clinic | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2017-02-16 | Capricor Inc. | Regulatory Capricor Therapeutics Provides Update on Natriuretic Peptide Program capricor.com ↗ |
All press releases naming this drug 4 releases
| Date | Issuer | Release |
|---|---|---|
| 2017-02-16 | Capricor Inc. | Capricor Therapeutics Provides Update on Natriuretic Peptide Program capricor.com ↗ |
| 2015-03-31 | Capricor Inc. | Capricor Therapeutics Completes Enrollment of Phase II Clinical Trial for Cenderitide to Treat Heart Failure capricor.com ↗ |
| 2015-03-05 | Capricor Inc. | Capricor Announces Enrollment of Its Phase II Clinical Trial for Cenderitide to Treat Heart Failure capricor.com ↗ |
| 2014-10-09 | Capricor Inc. | Capricor Therapeutics Announces Plans to Pursue a Cenderitide Clinical Program and Enters Into Research Support Agreement With Insulet Corporation capricor.com ↗ |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 12 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Cenderitide | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02359227 ↗ |
| Known as | CD-NP | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01407900 ↗ |
| Known as | Cenderitida | ChEMBL registry synonym — accepted as the source's own label CHEMBL2108721 ↗ |
| Action | Activate | “dual receptor (NPR-A and NPR-B) activation with CD-NP” NCT01407900 ↗ |
| Modality | Peptide | “CD-NP is a novel chimeric natriuretic peptide” NCT00620308 ↗ |
| Route | Intravenous | “24 hr intravenous infusion” NCT00557661 ↗ |